Updated US Guidelines for Using Moderna and Pfizer COVID-19 Vaccines in Children 6 Months to 5 Years Old (June 2022)
Updated
Abstract
On June 17, 2022, the FDA issued Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months to 5 years.
- The Moderna vaccine is administered as 2 doses of 25 µg each, 4 weeks apart for children aged 6 months-5 years.
- The Pfizer-BioNTech vaccine is given as 3 doses of 3 µg each, with specific intervals of 3 weeks between the first two doses and at least 8 weeks between the second and third doses for children aged 6 months-4 years.
- Both vaccines met the criteria for immunobridging, showing comparable neutralizing antibody levels in young children to those in young adults.
- Efficacy analyses were conducted during the predominance of the Omicron variant of SARS-CoV-2.
- No specific safety concerns were identified for either vaccine among recipients.
Simplified
Funding
Competing interests
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
PubMed